by The Tutu Team | Sep 1, 2017 | Uncategorized
Source: Breast Cancer Now Breast Cancer Now responds to NICE’s decision to reject fulvestrant as a first-line treatment for routine use on the NHS. Campaigns and policy The breast cancer drug fulvestrant is given by injection NICE has today (Friday 1 September)... 
by The Tutu Team | Apr 3, 2017 | Uncategorized
Author: Shobhit Seth / Source: Investopedia U.S. pharmaceutical giant Pfizer Inc. (PFE ) announced that it has secured approval from the U.S. Food And Drug Administration (FDA) for a supplemental New Drug Application (sNDA) for its first-in-class cyclin... 
by The Tutu Team | Mar 23, 2017 | Uncategorized
Author: Ines Martins / Source: Breast Cancer News Adding the CDK4/6 inhibitor abemaciclib to Faslodex (fulvestrant) is a promising way to treat patients with an advanced breast cancer who experienced a relapse or had their disease progress after endocrine... 